Stocks such as SoundHound AI, Arm, Nanox Imaging, and Recursion Pharmaceuticals have seen significant increases following Nvidia’s investment disclosure.
Since Nvidia disclosed its investments in SoundHound AI, the company’s shares have more than tripled in value, as per the 13F filing last month. Nvidia’s filing also unveiled stakes in other AI-focused companies such as Arm, Nanox Imaging, and Recursion Pharmaceuticals, all of which have experienced gains since the disclosure.
SoundHound AI (SOUN) shares have soared in value since Nvidia (NVDA) disclosed investments in the artificial intelligence (AI) company in a 13F filing last month, while shares of several other companies named in Nvidia’s disclosure also gained.
Nvidia’s 13F released on Feb. 14 revealed that the chipmaker held stock in SoundHoundAI as well as other AI-focused companies including Arm (ARM), Nanox Imaging (NNOX), and Recursion Pharmaceuticals (RXRX) as of Dec. 31, 2023.
Those stocks have also climbed since Nvidia reported its investments in the companies.
SoundHound AI Shares More Than Tripled Since Nvidia Disclosure
Since Nvidia’s disclosure last month, SoundHound AI shares have more than tripled in value, with its market capitalization reaching $2.75 billion. Nvidia said it held 1.73 million shares as of the end of 2023.
SoundHound AI offers a voice AI platform that provides brands with AI-powered voice tech to improve their customer experience.
Its customers range from White Castle, where SoundHoundAI tech powers the fast-food restaurant’s drive-thru lanes, to Stellantis (STLA), where the company’s AI voice tools are integrated into some of the automakers’ vehicles.
The company posted a “record quarter” in its most recent earnings report at the end of February, with revenue growing $80% from a year earlier. Following its earnings release, Wedbush analysts raised their price target for the stock to $9 from $5.
The firm has given the stock an “overperform” rating.
SoundHound AI shares finished 6.5% higher Friday at $8.91. The stock has more than quadrupled in value since the start of 2024.
Arm Added Over 5%
Arm has gained more than 5% since Nvidia disclosed its investments in the British semiconductor designer. Nvidia reported holding 1.96 million shares of Arm as of Dec. 31.
Arm earns royalties on products made by chip companies that license its designs to make products, and its customers include some of the world’s most valuable AI heavyweights such as Nvidia (NVDA), Google parent Alphabet (GOOGL), Qualcomm (QCOM), and Microsoft (MSFT), among others.
The company has benefited from the AI boom, reporting record-high revenue in early February.
Rosenblatt analysts said the firm has ” increased conviction that royalty trends are richening at a faster clip on the heels of more strategic licensing engagements that are increasingly AI-centric.” The analysts said, “like Nvidia in compute GPUs, Arm’s technology is becoming indispensable and more so as AI moves more and more to the Edge.”
Arm shares fell 3% Friday to $126.97, though they’ve gained more than 83% year to date.
Nanox Imaging Gained More Than 80%
Since Nvidia disclosed its investment in Nanox Imaging, shares have increased more than 80%. Nvidia said it held 59,632 shares as of the end of last year.
Nanox Imaging developed a digital X-ray source “enabling a cost reduction of imaging systems by orders of magnitude” that plans “mass deployment of imaging systems with the goal to drive early detection preventive healthcare as a new standard of global care,” according to the company’s website.
The health tech company has an AI segment, Nanox.AI, through which it offers solutions that “provide the ability to use AI to highlight and help identify patients with asymptomatic undetected chronic disease, initiating earlier diagnosis and preventative management.”
Nanox shares rose 7.6% Friday to $10.78, contributing to its more than 66% rise for 2024 so far.
Recursion Pharmaceuticals Climbed Over 14%
Recursion Pharmaceuticals shares added over 14% since Nvidia disclosed its investment in the AI biotech company, with Nvidia reporting over 7.71 million shares as of the end of December.
The biotech company says it leads “by decoding biology to industrialize drug discovery” that “leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias.”
The company reported a year-over-year decline in revenue its February earnings report, but highlighted progress in its scientific work.
Recursion shares rose 4% Friday to $11.22, supporting close to 14% growth since the start of 2024.
Nvidia shares were little changed Friday, edging 0.1% lower to $878.36. They’ve gained more than 82% year to date.
Source : Investopedia
